This counteracting action of MYCN’s intrinsic apoptosis-sensitizing effect may be triggered by increased MDM2 activity (despite the absence of gene amplification) [13,24], so that MYCN-directed MDM2 expression could constitutively weaken the pathway of p53 in neuroblastoma cells with amplified MYCN. The gene discussed is MYCN; the disease is neuroblastoma.